Guttman-Yassky E, Simpson E, Bissonnette R, Eichenfield L, Kabashima K, Luna P
Immunotherapy. 2025; 17(2):83-94.
PMID: 40012373
PMC: 11901500.
DOI: 10.1080/1750743X.2025.2464528.
Sato A, Nagai H, Suzuki A, Ito A, Matsuyama S, Shibui N
Front Immunol. 2025; 15:1473815.
PMID: 39867912
PMC: 11757143.
DOI: 10.3389/fimmu.2024.1473815.
Frecot D, Blaess S, Wagner T, Kaiser P, Traenkle B, Fandrich M
Front Immunol. 2024; 15:1480091.
PMID: 39474429
PMC: 11518761.
DOI: 10.3389/fimmu.2024.1480091.
Riaz F, Huang Z, Pan F
Front Immunol. 2023; 14:1280741.
PMID: 37936703
PMC: 10626496.
DOI: 10.3389/fimmu.2023.1280741.
Kwiatek M, Kojak A, Kwasniewska A
J Cardiovasc Dev Dis. 2023; 10(10).
PMID: 37887878
PMC: 10607140.
DOI: 10.3390/jcdd10100431.
YAP1 expression is associated with survival and immunosuppression in small cell lung cancer.
Chen P, Sun C, Wang H, Zhao W, Wu Y, Guo H
Cell Death Dis. 2023; 14(9):636.
PMID: 37752152
PMC: 10522695.
DOI: 10.1038/s41419-023-06053-y.
Lung tumor-infiltrating T have divergent transcriptional profiles and function linked to checkpoint blockade response.
Dykema A, Zhang J, Cheung L, Connor S, Zhang B, Zeng Z
Sci Immunol. 2023; 8(87):eadg1487.
PMID: 37713507
PMC: 10629528.
DOI: 10.1126/sciimmunol.adg1487.
Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy.
Sun Z, Chu Y, Xiao J, Yang Y, Meng F, Wang X
J Transl Med. 2023; 21(1):619.
PMID: 37700338
PMC: 10498626.
DOI: 10.1186/s12967-023-04504-w.
Versatile roles of innate lymphoid cells at the mucosal barrier: from homeostasis to pathological inflammation.
Ryu S, Lim M, Kim J, Kim H
Exp Mol Med. 2023; 55(9):1845-1857.
PMID: 37696896
PMC: 10545731.
DOI: 10.1038/s12276-023-01022-z.
Fundamental Characterization of Antibody Fusion-Single-Chain TNF Recombinant Proteins Directed against Costimulatory TNF Receptors Expressed by T-Lymphocytes.
Nagai H, Azuma M, Sato A, Shibui N, Ogawara S, Tsutsui Y
Cells. 2023; 12(12).
PMID: 37371066
PMC: 10297085.
DOI: 10.3390/cells12121596.
The Dawn of a New Era in Atopic Dermatitis Treatment.
Yamamura K, Nakahara T
J Clin Med. 2022; 11(20).
PMID: 36294465
PMC: 9605067.
DOI: 10.3390/jcm11206145.
Ox40-Cre-mediated deletion of BRD4 reveals an unexpected phenotype of hair follicle stem cells in alopecia.
Wen M, Ying Y, Xiao X, Arnold P, Wang G, Chu X
JCI Insight. 2022; 7(23).
PMID: 36256455
PMC: 9746908.
DOI: 10.1172/jci.insight.164534.
Systems biology models to identify the influence of SARS-CoV-2 infections to the progression of human autoimmune diseases.
Al-Mustanjid M, Mahmud S, Akter F, Rahman M, Hossen M, Rahman M
Inform Med Unlocked. 2022; 32:101003.
PMID: 35818398
PMC: 9259025.
DOI: 10.1016/j.imu.2022.101003.
Tumor-infiltrating OX40 lymphocytes is an independent positive prognostic factor for patients with pancreatic ductal adenocarcinoma.
Zhang Q, Rui W, Jiang Y, Yuan F, Chen Y, Guo X
Clin Transl Oncol. 2022; 24(10):2029-2038.
PMID: 35731350
DOI: 10.1007/s12094-022-02864-1.
A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy.
Fujiwara Y, Mittra A, Naqash A, Takebe N
Cancer Drug Resist. 2022; 3(3):252-275.
PMID: 35582437
PMC: 8992481.
DOI: 10.20517/cdr.2020.11.
Establishment of H3K9-methylated heterochromatin and its functions in tissue differentiation and maintenance.
Padeken J, Methot S, Gasser S
Nat Rev Mol Cell Biol. 2022; 23(9):623-640.
PMID: 35562425
PMC: 9099300.
DOI: 10.1038/s41580-022-00483-w.
A multivariate modeling framework to quantify immune checkpoint context-dependent stimulation on T cells.
Karpf L, Trichot C, Faucheux L, Legbre I, Grandclaudon M, Lahoute C
Cell Discov. 2022; 8(1):1.
PMID: 34983927
PMC: 8727669.
DOI: 10.1038/s41421-021-00352-4.
Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment.
Chen P, Wang H, Zhao L, Guo H, Zhang L, Zhang W
Front Oncol. 2021; 11:713853.
PMID: 34900670
PMC: 8652148.
DOI: 10.3389/fonc.2021.713853.
Immune Checkpoints and Innate Lymphoid Cells-New Avenues for Cancer Immunotherapy.
Jacquelot N, Ghaedi M, Warner K, Chung D, Crome S, Ohashi P
Cancers (Basel). 2021; 13(23).
PMID: 34885076
PMC: 8657134.
DOI: 10.3390/cancers13235967.
Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination.
Chu Y, Li R, Qian L, Liu F, Xu R, Meng F
Cancer Sci. 2021; 112(11):4490-4500.
PMID: 34537997
PMC: 8586665.
DOI: 10.1111/cas.15145.
